Acute SCI Therapeutics Market is Forecast to Show Slow Growth to 2017
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Acute Spinal Cord Injury (ASCI) Therapeutics - PipelineAssessment and Market Forecasts to 2017
Acute SCI Therapeutics Market is Forecast to Show Slow Growth to 2017 GlobalData estimated the acute spinal cord injury (ASCI) therapeutics market to be worth $44.78m in 2010 and forecasts it to grow at a CAGR of 6.3% to reach $68.76m in 2017. This predicted growth is primarily attributed to the increasing incidence of SCIs and a larger treatment seeking population. There is only one molecule, Lyrica (pregabalin) in Phase III of the pipeline, which targets the pain associated with SCIs. This molecule only offers symptomatic relief and is not likely to have a significant impact on the ASCI therapeutics market. The lack of specific approved neuroprotective and neuroregenerative therapies is a barrier for the acute SCI therapeutics market. Current Competition in the Acute SCI Market is Weak GlobalData’s analysis reveals that the current competition in the ASCI therapeutics market is weak. The market lacks a therapy specifically approved by the FDA (Food and Drug Administration) or the EMEA (European Medicines Agency) for the treatment of SCIs. Medrol (methylprednisolone), which helps to reduce swelling in the spinal cord, is widely prescribed as an off-label drug. However, it is unable to completely serve the market’s unmet needs. The absence of effective treatment options clearly signifies that the current competition in the ASCI market is weak. Several First-in-Class Drugs in the ASCI Therapeutics Pipeline
The pipeline consists of 19 products in different stages of development. Neuropathic pain is a common symptom among patients. Pregabalin, which targets neuropathic pain, is currently in Phase III. There are 12 drugs in the preclinical and discovery stages of development. However, the later stages of the developmental pipeline contain only three molecules. Phase III contains pregabalin, which is a voltage gated calcium channel modulator. Phase II includes, Umbilical Cord Blood Mononuclear Cell Transplants, which are aimed at improving functional recovery in patients, and ProCord, an autologous activated macrophage therapy, aimed at facilitating neuroprotecion and wound healing. All of the drugs in the pipeline are first-in-class drugs, with 84% of the pipeline dominated by molecules exhibiting neuroprotective and neuronal regeneration characteristics. Out of the 84%, the molecules in the discovery and the preclinical stages contribute around 88%. This suggests that the pipeline intensity in the clinical Phases is weak and that research and development (R&D) is mainly focused in the discovery and preclinical stages. These products are expected to meet some unmet needs and will provide physicians with better options for treating SCIs. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Acute-Respiratory-Distress-Syndrome-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report
High Unmet Need in the Acute SCI Therapeutics Market The ASCI therapeutics market has a high unmet need, which implies that the market is not well served by the current products. This leaves scope for the launch of improved products that can capture the ASCI therapeutics market. The current market has no approved treatment options; therefore, a significant need exists for neuroprotective and neuroregeneration treatment. The ASCI market continues to present opportunities for new entrants. However, in order to capitalize on the opportunity posed by the high unmet needs in the existing market, the products in the pipeline would need to overcome the weaknesses of the currently available off-label products used in the treatment of ASCI. This would require them to perform neuroprotective and neuroregeneration functions rather than only providing symptomatic relief. GlobalData, the industry analysis specialist, has released its new report, “Acute Spinal Cord Injury (ASCI) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global SCI market. The report identifies the key trends shaping and driving the global ASCI market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global ASCI sector. This report is built using data and information sourced from proprietary databases,
For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Acute-Respiratory-Distress-Syndrome-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report Visit our report store: http://www.globaldata.com For more details contact: email@example.com North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782